CLSA analysts downgraded Dr. Reddy's Laboratories shares, trading on both BSE (DRRD:IN) and NYSE (NYSE:RDY), from a Hold to an Underperform rating, adjusting the price target from INR1,140 to INR1,090 ...

Healthcare stocks see mixed performance as Dr Lal Pathlabs and Aurobindo Pharma rise over 2% after CLSA upgrades their ...

The firm expects mid-single-digit price erosion in generic drugs and heightened competition for key medications, potentially ...

This steady growth in HDFC Bank's core earnings - both NII and net profit - came in despite a marginal rise in NPAs and NPA ...

CLSA has included Zomato in its High Conviction Outperform list, maintaining an "Overweight" rating and increasing the target ...

2025 Market Outlook: CLSA anticipates a challenging year for the Nifty in 2025, driven by an uncertain and risky global macro environment coupled with a near-term economic slowdown in India.

Vikash Kumar Jain, India Strategist and Head of Research at CLSA, predicts 2025 will be a year of consolidation for Indian markets. He noted that the consolidation trend, which began in October, could ...

This is the first time Indus Towers has received a ₹575 target, making it the highest among analysts covering the telecom ...

The brokerage firm has also added Zomato to its high conviction outperform list, saying the recent correction is a buying ...

HCLTech declared a dividend of Rs 18 per share, including a special Rs 6 per share dividend to commemorate 25 years since its ...

Shares of Zomato surged as much as 7.27% to reach INR 261.75 during the intraday trading session on the BSE today (January 16 ...